

Table 5: Consensus guidelines on the Use of Hydroxychloroquine (n =139)				
	Healthy patient	Healthy patient with contact	Sick patient - COVID-19 suspected	Sick patient - COVID-19 positive
To be started	59 (42.4%)	65 (46.8%)	80 (57.6%)	91 (65.5%)
To be continued	126 (90.6%)	129 (92.8%)	125 (89.9%)	128 (92.1%)

Consensus for “Yes”

Table 5A: Consensus guidelines on the Use of Hydroxychloroquine – As per years of experience and uveitis patients per year

	Uveitis specialists' expertise		Healthy patient – without contact	Healthy patient - with contact	Sick patient - COVID-19 suspected	Sick patient - COVID-19 positive
To be started	Years of experience in uveitis	≤ 15 (n = 80)	36 (45.00 %)	39 (48.75 %)	50 (62.50 %)	54 (67.50 %)
		> 15 (n = 59)	23 (38.98 %)	26 (44.07 %)	30 (50.85 %)	37 (62.71 %)
	Uveitis patients on IMT/year	< 300 (n = 85)	38 (44.71 %)	42 (49.41 %)	49 (57.65 %)	55 (64.71 %)
		≥ 300 (n =54)	21 (38.89 %)	23 (42.59 %)	31 (57.41 %)	36 (66.67 %)
To be continued	Years of experience in uveitis	≤ 15 (n = 80)	73 (91.25 %)	76 (95 %)	73 (91.25 %)	73 (91.25 %)
		> 15 (n = 59)	53 (89.83 %)	53 (89.83 %)	52 (88.14 %)	55 (93.22 %)
	Uveitis patients on IMT/year	< 300 (n = 85)	78 (91.76 %)	80 (94.12 %)	75 (88.24 %)	76 (89.41 %)
		≥ 300 (n =54)	48 (88.89 %)	49 (90.74 %)	50 (92.59 %)	52 (96.30 %)

Table 5B: Consensus guidelines on the Use of Hydroxychloroquine – As per geographical region

	Experts' geographical area	Healthy patient – without contact	Healthy patient - with contact	Sick patient - COVID-19 suspected	Sick patient - COVID-19 positive
To be started	Asia (n = 44)	21 (47.73 %)	26 (59.09 %)	31 (70.45 %)	33 (75 %)
	Africa (n = 3)	1 (33.33 %)	3 (100 %)	2 (66.67 %)	2 (66.67 %)
	Europe (n = 43)	19 (44.19 %)	19 (44.19 %)	26 (60.47 %)	28 (65.12 %)
	North America (n = 34)	13 (38.24 %)	12 (35.29 %)	13 (38.24 %)	19 (55.88 %)
	South America (n =7)	4 (57.14 %)	4 (57.14 %)	5 (71.43 %)	6 (85.71 %)
	Oceania (n = 8)	1 (12.5 %)	1 (12.5 %)	3 (37.5 %)	3 (37.5 %)
To be continued	Asia (n = 44)	38 (86.36 %)	40 (90.91 %)	38 (86.36 %)	40 (90.91 %)
	Africa (n = 3)	3 (100 %)	3 (100 %)	3 (100 %)	3 (100 %)
	Europe (n = 43)	41 (95.35 %)	41 (95.35 %)	40 (93.02 %)	40 (93.02 %)
	North America (n = 34)	32 (94.12 %)	32 (94.12 %)	31 (91.18 %)	32 (94.12 %)
	South America (n =7)	6 (85.71 %)	7 (100 %)	7 (100 %)	7 (100 %)
	Oceania (n = 8)	6 (75 %)	6 (75 %)	6 (75 %)	6 (75 %)

Consensus for “Yes”